Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Global Neurosciences Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of GBM
Grade IV GBM tumors that have recurred after total resection
Age \> 18 years
At least four weeks following any recent surgery
Patients must have a Karnofsky performance status ≥60% and an expected survival of ≥ three months.
No IV chemotherapy for three weeks prior to treatment under this research protocol and no external beam radiation for four weeks prior to treatment under this research protocol.
Patients must have adequate hematologic reserve
Pre-enrollment coagulation parameters (PT and PTT) must be adequate.
Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study.
Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening.
You may not be if
Women who are pregnant or lactating.
Women of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period.
Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring.
Clareo Health | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
